U.S. Markets open in 7 hrs 14 mins

Acerus Pharmaceuticals Corporation (ASPCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.85000.0000 (0.00%)
At close: 12:34PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8500
BidN/A x N/A
AskN/A x N/A
Day's Range1.8500 - 1.8500
52 Week Range0.0200 - 8.0000
Avg. Volume22
Market Cap2.845B
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateMar 09, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Acerus Announces Initiation of Strategic Review

    Ernst & Young Orenda Corporate Finance Inc. (“EY”) engaged as independent financial advisors TORONTO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Board of Directors has determined to undertake a strategic review of capital and business alternatives, including a possible debt or equity financing, asset sale, M&A, or licensing transaction. The Board has struck a committee of independent director

  • GlobeNewswire

    Acerus Announces Resignation of CFO Effective November 20, 2022

    TORONTO, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that Robert Motz has informed the Company of his decision to resign as Chief Financial Officer effective November 20, 2022. Acerus has begun a process to search for a new CFO and will provide an update at a future date. “I would like to thank Bob for his contributions over the past four years,” said Edward Gudaitis, President and Chief Executive Officer

  • GlobeNewswire

    Acerus Reports Second Quarter 2022 Financial Results

    TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and six-month period ended June 30, 2022. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Recent Highlights Total Natesto® prescriptions in the US rose 47% year-over-year in the second quarter of 2022 and were up approxima